{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T17:02:07Z","timestamp":1772816527869,"version":"3.50.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,7,23]],"date-time":"2012-07-23T00:00:00Z","timestamp":1343001600000},"content-version":"vor","delay-in-days":113,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.6061\/clinics\/2012(04)13","type":"journal-article","created":{"date-parts":[[2012,4,5]],"date-time":"2012-04-05T11:30:42Z","timestamp":1333625442000},"page":"389-394","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Castration-resistant prostate cancer: systemic therapy in 2012"],"prefix":"10.1016","volume":"67","author":[{"given":"Fernando C.","family":"Maluf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oren","family":"Smaletz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Herchenhorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.6061\/clinics\/2012(04)13_bib1","series-title":"World Cancer Report","article-title":"International Agency for Research on Cancer","author":"World Health Organization","year":"2008"},{"issue":"5","key":"10.6061\/clinics\/2012(04)13_bib2","first-page":"277","article-title":"Cancer statistics","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"issue":"9625","key":"10.6061\/clinics\/2012(04)13_bib3","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S0140-6736(08)60729-1","article-title":"Prostate cancer","volume":"371","author":"Damber","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.6061\/clinics\/2012(04)13_bib4","first-page":"237","article-title":"International trends in prostate-cancer mortality: the decrease is continuing and spreading","volume":"15","author":"Baade","year":"2004","journal-title":"Cancer Causes Control"},{"issue":"3","key":"10.6061\/clinics\/2012(04)13_bib5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/annonc\/mdl498","article-title":"Estimates of the cancer incidence and mortality in Europe in 2006","volume":"18","author":"Ferlay","year":"2007","journal-title":"Ann Oncol"},{"key":"10.6061\/clinics\/2012(04)13_bib6","author":"Brasil"},{"issue":"5","key":"10.6061\/clinics\/2012(04)13_bib7","first-page":"300","article-title":"Advances in prostate cancer chemotherapy: a new era begins","volume":"55","author":"Pienta","year":"2005","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.6061\/clinics\/2012(04)13_bib8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0090-4295(99)00471-9","article-title":"Clinical states in prostate cancer: toward a dynamic model of disease progression","volume":"55","author":"Scher","year":"2000","journal-title":"Urology"},{"issue":"3","key":"10.6061\/clinics\/2012(04)13_bib9","first-page":"154","article-title":"The current state of hormonal therapy for prostate cancer","volume":"52","author":"Hellerstedt","year":"2002","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.6061\/clinics\/2012(04)13_bib10","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1177\/107327480401100604","article-title":"Management of androgen-independent prostate cancer","volume":"11","author":"Diaz","year":"2004","journal-title":"Cancer Control"},{"key":"10.6061\/clinics\/2012(04)13_bib11","doi-asserted-by":"crossref","unstructured":"Crawford ED, Petrylak D. Castration-resistant prostate cancer: descriptive yet pejorative. J Clin Oncol. 28(23):e408. Epub 2010\/06\/16","DOI":"10.1200\/JCO.2010.28.7664"},{"issue":"7","key":"10.6061\/clinics\/2012(04)13_bib12","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.6061\/clinics\/2012(04)13_bib13","doi-asserted-by":"crossref","unstructured":"de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 376(9747):1147-54. Epub 2010\/10\/05.","DOI":"10.1016\/S0140-6736(10)61389-X"},{"key":"10.6061\/clinics\/2012(04)13_bib14","doi-asserted-by":"crossref","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 363(5):411-22. Epub 2010\/09\/08.","DOI":"10.1056\/NEJMoa1001294"},{"key":"10.6061\/clinics\/2012(04)13_bib15","doi-asserted-by":"crossref","unstructured":"Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol. 28(9):1496-501. Epub 2010\/02\/18.","DOI":"10.1200\/JCO.2009.25.9259"},{"issue":"33","key":"10.6061\/clinics\/2012(04)13_bib16","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.1200\/JCO.2007.13.4536","article-title":"American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer","volume":"25","author":"Basch","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.6061\/clinics\/2012(04)13_bib17","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1200\/JCO.1997.15.1.382","article-title":"Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm","volume":"15","author":"Small","year":"1997","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.6061\/clinics\/2012(04)13_bib18","doi-asserted-by":"crossref","first-page":"8253","DOI":"10.1200\/JCO.2005.03.4777","article-title":"Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis","volume":"23","author":"Scher","year":"2005","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.6061\/clinics\/2012(04)13_bib19","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/sj.bjc.6603223","article-title":"Improving the outcome of patients with castration-resistant prostate cancer through rational drug development","volume":"95","author":"Attard","year":"2006","journal-title":"Br J Cancer"},{"issue":"21","key":"10.6061\/clinics\/2012(04)13_bib20","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJM199505253322101","article-title":"Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer","volume":"332","author":"Taplin","year":"1995","journal-title":"N Engl J Med"},{"issue":"6","key":"10.6061\/clinics\/2012(04)13_bib21","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1200\/JCO.2004.06.037","article-title":"Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)","volume":"22","author":"Small","year":"2004","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.6061\/clinics\/2012(04)13_bib22","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.urology.2003.09.005","article-title":"The patient with hormone-refractory prostate cancer: determining who, when, and how to treat","volume":"62","author":"Kent","year":"2003","journal-title":"Urology"},{"issue":"2","key":"10.6061\/clinics\/2012(04)13_bib23","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ucl.2005.12.006","article-title":"Changing perspectives of the role of chemotherapy in advanced prostate cancer","volume":"33","author":"Burgess","year":"2006","journal-title":"Urol Clin North Am"},{"issue":"15","key":"10.6061\/clinics\/2012(04)13_bib24","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"issue":"15","key":"10.6061\/clinics\/2012(04)13_bib25","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1200\/JCO.2008.19.9810","article-title":"Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916","volume":"27","author":"Hussain","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.6061\/clinics\/2012(04)13_bib26","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1200\/JCO.1985.3.6.827","article-title":"A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma","volume":"3","author":"Eisenberger","year":"1985","journal-title":"J Clin Oncol"},{"issue":"3 Suppl","key":"10.6061\/clinics\/2012(04)13_bib27","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1002\/1097-0142(19930201)71:3+<1098::AID-CNCR2820711432>3.0.CO;2-G","article-title":"Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer","volume":"71","author":"Yagoda","year":"1993","journal-title":"Cancer"},{"issue":"4","key":"10.6061\/clinics\/2012(04)13_bib28","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0959-8049(96)00510-2","article-title":"Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer","volume":"33","author":"Raghavan","year":"1997","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.6061\/clinics\/2012(04)13_bib29","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3109\/07357909609076896","article-title":"Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer","volume":"14","author":"Figg","year":"1996","journal-title":"Cancer Invest"},{"issue":"4","key":"10.6061\/clinics\/2012(04)13_bib30","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1200\/JCO.1993.11.4.607","article-title":"Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer","volume":"11","author":"Kelly","year":"1993","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.6061\/clinics\/2012(04)13_bib31","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1200\/JCO.1999.17.11.3461","article-title":"Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group","volume":"17","author":"Bubley","year":"1999","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.6061\/clinics\/2012(04)13_bib32","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1200\/JCO.2005.08.156","volume":"23","author":"Collette","year":"2005","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.6061\/clinics\/2012(04)13_bib33","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.2007.11.4769","article-title":"Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer","volume":"25","author":"Armstrong","year":"2007","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.6061\/clinics\/2012(04)13_bib34","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1200\/JCO.2002.11.021","article-title":"Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration","volume":"20","author":"Smaletz","year":"2002","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.6061\/clinics\/2012(04)13_bib35","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.1999.17.10.3160","article-title":"Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial","volume":"17","author":"Hudes","year":"1999","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.6061\/clinics\/2012(04)13_bib36","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/sj.bjc.6601468","article-title":"Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer","volume":"90","author":"Albrecht","year":"2004","journal-title":"Br J Cancer"},{"issue":"12","key":"10.6061\/clinics\/2012(04)13_bib37","first-page":"1133","article-title":"Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer","volume":"67","author":"Osborne","year":"1983","journal-title":"Cancer Treat Rep"},{"issue":"5","key":"10.6061\/clinics\/2012(04)13_bib38","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1200\/JCO.1989.7.5.590","article-title":"Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response","volume":"7","author":"Tannock","year":"1989","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.6061\/clinics\/2012(04)13_bib39","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","article-title":"Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points","volume":"14","author":"Tannock","year":"1996","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.6061\/clinics\/2012(04)13_bib40","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1200\/JCO.1999.17.8.2506","article-title":"Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study","volume":"17","author":"Kantoff","year":"1999","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.6061\/clinics\/2012(04)13_bib41","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0022-5347(05)64163-8","article-title":"Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer","volume":"168","author":"Berry","year":"2002","journal-title":"J Urol"},{"issue":"9","key":"10.6061\/clinics\/2012(04)13_bib42","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1023\/A:1012258723075","article-title":"Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer","volume":"12","author":"Beer","year":"2001","journal-title":"Ann Oncol"},{"issue":"4 Suppl 15","key":"10.6061\/clinics\/2012(04)13_bib43","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0093-7754(01)90149-6","article-title":"Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate","volume":"28","author":"Berry","year":"2001","journal-title":"Semin Oncol"},{"issue":"15","key":"10.6061\/clinics\/2012(04)13_bib44","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"issue":"7","key":"10.6061\/clinics\/2012(04)13_bib45","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/sj.bjp.0705150","article-title":"Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats","volume":"138","author":"Cisternino","year":"2003","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.6061\/clinics\/2012(04)13_bib46","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1158\/1078-0432.CCR-08-0596","article-title":"Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors","volume":"15","author":"Mita","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.6061\/clinics\/2012(04)13_bib47","article-title":"Preclinical evaluation of TXD258, a novel taxoid","volume":"41","author":"Bissery","year":"2000","journal-title":"Proc Am Assoc Cancer Res"},{"issue":"9","key":"10.6061\/clinics\/2012(04)13_bib48","first-page":"1547","article-title":"A multicenter phase II study of XRP6258 administered as a 1-h i.v","volume":"19","author":"Pivot","year":"2008","journal-title":"infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol"},{"issue":"28","key":"10.6061\/clinics\/2012(04)13_bib49","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","volume":"26","author":"Attard","year":"2008","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.6061\/clinics\/2012(04)13_bib50","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1200\/JCO.2008.20.0642","article-title":"Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer","volume":"27","author":"Attard","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.6061\/clinics\/2012(04)13_bib51","doi-asserted-by":"crossref","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 364(21):1995-2005. Epub 2011\/05\/27.","DOI":"10.1056\/NEJMoa1014618"},{"issue":"16","key":"10.6061\/clinics\/2012(04)13_bib52","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1002\/cncr.24429","article-title":"Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer","volume":"115","author":"Higano","year":"2009","journal-title":"Cancer"},{"key":"10.6061\/clinics\/2012(04)13_bib53","doi-asserted-by":"crossref","unstructured":"Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 375(9724):1437-46. Epub 2010\/04\/20.","DOI":"10.1016\/S0140-6736(10)60172-9"},{"issue":"suppl","key":"10.6061\/clinics\/2012(04)13_bib54","first-page":"18s","article-title":"A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401","volume":"28","author":"Kelly","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3 Suppl","key":"10.6061\/clinics\/2012(04)13_bib55","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/cncr.11130","article-title":"Targeting prostate cancer bone metastases","volume":"97","author":"Logothetis","year":"2003","journal-title":"Cancer"},{"issue":"9","key":"10.6061\/clinics\/2012(04)13_bib56","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/j.1464-410X.2007.07364.x","article-title":"Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases","volume":"101","author":"Saad","year":"2008","journal-title":"BJU Int"},{"issue":"11","key":"10.6061\/clinics\/2012(04)13_bib57","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"Journal of the National Cancer Institute"},{"issue":"9253","key":"10.6061\/clinics\/2012(04)13_bib58","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0140-6736(00)03639-4","article-title":"Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial","volume":"357","author":"Tu","year":"2001","journal-title":"Lancet"},{"issue":"suppl","key":"10.6061\/clinics\/2012(04)13_bib59","first-page":"18s","article-title":"A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer","volume":"28","author":"Fizazi","year":"2010","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.6061\/clinics\/2012(04)13_bib60","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.2008.20.4164","article-title":"Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer","volume":"27","author":"Morris","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.6061\/clinics\/2012(04)13_bib61","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/nm0995-944","article-title":"Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate","volume":"1","author":"Nelson","year":"1995","journal-title":"Nat Med"},{"key":"10.6061\/clinics\/2012(04)13_bib62","doi-asserted-by":"crossref","unstructured":"Chadha MK, Tian L, Mashtare T, Payne V, Silliman C, Levine E, et al. Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer. Cancer. 116(9):2132-9. Epub 2010\/02\/19.","DOI":"10.1002\/cncr.24973"},{"issue":"5","key":"10.6061\/clinics\/2012(04)13_bib63","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.eururo.2008.11.002","article-title":"Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial","volume":"55","author":"James","year":"2009","journal-title":"Eur Urol"},{"issue":"suppl","key":"10.6061\/clinics\/2012(04)13_bib64","first-page":"15s","article-title":"Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): Results from the phase III ASCENT2 trial","volume":"28","author":"Scher","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S180759322201849X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S180759322201849X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/clinics.org.br\/uploads\/artigos\/cln-67-04\/cln-67-04-389.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:08:05Z","timestamp":1761721685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S180759322201849X"},"secondary":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_abstract&pid=S1807-59322012000400013&lng=en&nrm=iso","label":"SCIELO"},{"URL":"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3317249\/?report=classic","label":"PMC"}]},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S180759322201849X"],"URL":"https:\/\/doi.org\/10.6061\/clinics\/2012(04)13","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Castration-resistant prostate cancer: systemic therapy in 2012","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.6061\/clinics\/2012(04)13","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 CLINICS. Published by Elsevier Spain","name":"copyright","label":"Copyright"}]}}